660 related articles for article (PubMed ID: 11544296)
1. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
[TBL] [Abstract][Full Text] [Related]
3. The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
Ueda Y; Hagihara M; Gansuvd B; Yu Y; Masui A; Okamoto A; Higuchi A; Tazume K; Kato S; Hotta T
Cancer Immunol Immunother; 2003 Oct; 52(10):625-31. PubMed ID: 12802518
[TBL] [Abstract][Full Text] [Related]
4. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
5. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.
Stirnemann K; Romero JF; Baldi L; Robert B; Cesson V; Besra GS; Zauderer M; Wurm F; Corradin G; Mach JP; Macdonald HR; Donda A
J Clin Invest; 2008 Mar; 118(3):994-1005. PubMed ID: 18259610
[TBL] [Abstract][Full Text] [Related]
6. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells.
Takahashi T; Nieda M; Koezuka Y; Nicol A; Porcelli SA; Ishikawa Y; Tadokoro K; Hirai H; Juji T
J Immunol; 2000 May; 164(9):4458-64. PubMed ID: 10779745
[TBL] [Abstract][Full Text] [Related]
7. CD1d-independent NKT cells in beta 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells.
Maeda M; Shadeo A; MacFadyen AM; Takei F
J Immunol; 2004 May; 172(10):6115-22. PubMed ID: 15128797
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
Metelitsa LS; Weinberg KI; Emanuel PD; Seeger RC
Leukemia; 2003 Jun; 17(6):1068-77. PubMed ID: 12764370
[TBL] [Abstract][Full Text] [Related]
9. Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro.
Ishihara S; Nieda M; Kitayama J; Osada T; Yabe T; Kikuchi A; Koezuka Y; Porcelli SA; Tadokoro K; Nagawa H; Juji T
J Immunol; 2000 Aug; 165(3):1659-64. PubMed ID: 10903777
[TBL] [Abstract][Full Text] [Related]
10. Human NKT cells express granulysin and exhibit antimycobacterial activity.
Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells.
Takahashi T; Chiba S; Nieda M; Azuma T; Ishihara S; Shibata Y; Juji T; Hirai H
J Immunol; 2002 Apr; 168(7):3140-4. PubMed ID: 11907064
[TBL] [Abstract][Full Text] [Related]
12. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
13. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-gamma release by liver NKT cells.
Trobonjaca Z; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 2001 Aug; 167(3):1413-22. PubMed ID: 11466360
[TBL] [Abstract][Full Text] [Related]
14. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
15. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.
Trobonjaca Z; Kröger A; Stober D; Leithäuser F; Möller P; Hauser H; Schirmbeck R; Reimann J
J Immunol; 2002 Apr; 168(8):3763-70. PubMed ID: 11937527
[TBL] [Abstract][Full Text] [Related]
16. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
17. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells.
Eberl G; MacDonald HR
Eur J Immunol; 2000 Apr; 30(4):985-92. PubMed ID: 10760785
[TBL] [Abstract][Full Text] [Related]
18. CD1d1 displayed on cell size beads identifies and enriches an NK cell population negatively regulated by CD1d1.
Huang MM; Borszcz P; Sidobre S; Kronenberg M; Kane KP
J Immunol; 2004 May; 172(9):5304-12. PubMed ID: 15100269
[TBL] [Abstract][Full Text] [Related]
19. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
[TBL] [Abstract][Full Text] [Related]
20. CD1d-specific NK1.1+ T cells with a transgenic variant TCR.
Sköld M; Faizunnessa NN; Wang CR; Cardell S
J Immunol; 2000 Jul; 165(1):168-74. PubMed ID: 10861049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
